Reportlinker Adds Shire plc: PharmaVitae Profile

NEW YORK, Jan. 13, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Shire plc: PharmaVitae Profile

http://www.reportlinker.com/p0177526/Shire-plc-PharmaVitae-Profile.html

Introduction

This analysis examines the historical and forecast performance for Shire in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs.

Features and benefits

* Gain insight into Shire's strategic outlook across the next 6 years* Analyze company sales forecasts by product, therapy area, lifecycle stage, geography, molecule type and source

Highlights

Strategic insight into the prospects for Shire over the next six years. Picking out key strengths, weaknesses, opportunities and threats and evaluating the company's prescription pharmaceuticals outlook using a variety of cuts of the historical and forecast sales.

Your key questions answered

* Benchmark Shire's performance against key rivals in the prescription pharmaceutical sector* Shire has pulled off the feat of overcoming the loss of its largest product by a long way, Adderall XR. Assess the strategies used to achieve this.* Diversifying away from key historical markets such as ADHD, Shire has built an enviable portfolio of treatments for rare genetic disorders.

To order this report:

: Shire plc: PharmaVitae Profile

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Contact Nicolas Bombourg

Reportlinker

Email: [email protected]

US: (805)652-2626

Intl: +1 805-652-2626



SOURCE Reportlinker

Suggested Articles

Monday, Bernstein analysts echoed what many were probably thinking about Novo Nordisk’s Rybselsus price: “Finally we can stop talking about it.”

Low interest rates and strong stock valuations are two top reasons why U.S. drugmakers are on the move for deals.

Despite a 45% premium offered to Allergan investors through the AbbVie buyout, one investor is suing to block the deal.